# Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT07163273** · PHASE2 · RECRUITING · sponsor: **Northwell Health** · enrollment: 41 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** NALIRIFOX
- **DRUG:** Gemcitabine plus nab-Paclitaxel (GnP)

## Key facts

- **NCT ID:** NCT07163273
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2027-06-20
- **Final completion:** 2027-06-20
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07163273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07163273, "Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07163273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*